2 No-Brainer Growth Stocks to Buy and Hold Forever
Don't let market volatility convince you otherwise: Investing in stocks remains one of the best ways to accumulate capital over long periods. It can be hard to remember that when equities are falling, and the market faces significant uncertainty due to macroeconomic factors -- precisely what we have experienced in 2025. However, no matter what is going on right now, buying shares in excellent companies will generate outsized returns in the next five, 10, or even 20 years. Companies that can last -- and thrive -- that long are rare, but let's consider two brilliant examples investors should strongly consider today: Eli Lilly (NYSE: LLY) and Shopify (NYSE: SHOP).Drugs that help manage or cure severe illnesses are always in high demand, something that won't change anytime soon. Eli Lilly, a leading pharmaceutical company, develops and markets therapies across various areas, including immunology, oncology, and especially endocrine disorders like diabetes. Eli Lilly is also establishing itself as a top player in the fast-growing market for weight management medicines. The company's current lineup is helping drive impressive top-line growth for a drugmaker its size.In 2024, Eli Lilly's revenue increased by 32% year over year to about $45 billion -- well above the average for its similarly sized peers. The company's guidance for 2025 implies top-line growth of 32% at the mid-point. Several of Eli Lilly's medicines should help drive excellent results well into the next decade. These include its diabetes drug Mounjaro, anti-obesity medicine Zepbound, Kisunla, which was approved just last year to treat Alzheimer's disease, Ebglyss, another newer product with an indication in eczema, and more.Continue reading
Don't let market volatility convince you otherwise: Investing in stocks remains one of the best ways to accumulate capital over long periods. It can be hard to remember that when equities are falling, and the market faces significant uncertainty due to macroeconomic factors -- precisely what we have experienced in 2025. However, no matter what is going on right now, buying shares in excellent companies will generate outsized returns in the next five, 10, or even 20 years. Companies that can last -- and thrive -- that long are rare, but let's consider two brilliant examples investors should strongly consider today: Eli Lilly (NYSE: LLY) and Shopify (NYSE: SHOP).
Drugs that help manage or cure severe illnesses are always in high demand, something that won't change anytime soon. Eli Lilly, a leading pharmaceutical company, develops and markets therapies across various areas, including immunology, oncology, and especially endocrine disorders like diabetes. Eli Lilly is also establishing itself as a top player in the fast-growing market for weight management medicines. The company's current lineup is helping drive impressive top-line growth for a drugmaker its size.
In 2024, Eli Lilly's revenue increased by 32% year over year to about $45 billion -- well above the average for its similarly sized peers. The company's guidance for 2025 implies top-line growth of 32% at the mid-point. Several of Eli Lilly's medicines should help drive excellent results well into the next decade. These include its diabetes drug Mounjaro, anti-obesity medicine Zepbound, Kisunla, which was approved just last year to treat Alzheimer's disease, Ebglyss, another newer product with an indication in eczema, and more.
